Overview

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

Status:
NOT_YET_RECRUITING
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets
Phase:
PHASE2
Details
Lead Sponsor:
JKT Biopharma Co., Ltd.
Treatments:
Control Groups